Viking Therapeutics Inc (VKTX)
75.41
-1.02
(-1.33%)
USD |
NASDAQ |
May 02, 14:30
Viking Therapeutics Cash from Operations (Quarterly): -6.134M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -6.134M |
| December 31, 2023 | -17.64M |
| September 30, 2023 | -19.66M |
| June 30, 2023 | -11.44M |
| March 31, 2023 | -24.64M |
| December 31, 2022 | -10.93M |
| September 30, 2022 | -13.50M |
| June 30, 2022 | -13.44M |
| March 31, 2022 | -10.53M |
| December 31, 2021 | -12.35M |
| September 30, 2021 | -10.93M |
| June 30, 2021 | -13.43M |
| March 31, 2021 | -10.88M |
| December 31, 2020 | -5.486M |
| September 30, 2020 | -5.323M |
| June 30, 2020 | -6.666M |
| March 31, 2020 | -4.302M |
| December 31, 2019 | -11.74M |
| September 30, 2019 | -3.398M |
| June 30, 2019 | -6.459M |
| March 31, 2019 | -3.152M |
| December 31, 2018 | -2.679M |
| Date | Value |
|---|---|
| September 30, 2018 | -5.503M |
| June 30, 2018 | -5.27M |
| March 31, 2018 | -5.303M |
| December 31, 2017 | -3.947M |
| September 30, 2017 | -3.329M |
| June 30, 2017 | -4.202M |
| March 31, 2017 | -3.28M |
| December 31, 2016 | -2.465M |
| September 30, 2016 | -2.654M |
| June 30, 2016 | -3.227M |
| March 31, 2016 | -2.725M |
| December 31, 2015 | -3.299M |
| September 30, 2015 | -3.400M |
| June 30, 2015 | -1.621M |
| March 31, 2015 | -0.4109M |
| December 31, 2014 | -0.441M |
| September 30, 2014 | -0.6098M |
| June 30, 2014 | -0.4399M |
| March 31, 2014 | -0.1008M |
| June 30, 2013 | -0.0099M |
| March 31, 2013 | 0.00 |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-24.64M
Minimum
Mar 2023
-3.398M
Maximum
Sep 2019
-10.94M
Average
-10.93M
Median
Sep 2021
Cash from Operations (Quarterly) Benchmarks
| Eli Lilly and Co | 1.166B |
| Pfizer Inc | 5.24B |
| Madrigal Pharmaceuticals Inc | -79.93M |
| Akero Therapeutics Inc | -48.63M |
| Terns Pharmaceuticals Inc | -19.32M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -459.79M |
| Cash from Financing (Quarterly) | 606.04M |
| Free Cash Flow | -54.87M |
| Free Cash Flow Per Share (Quarterly) | -0.0593 |
| Free Cash Flow Yield | -0.72% |